Lion Biotechnologies Inc. (LBIO) Hits New 12-Month High at $9.58
Shares of Lion Biotechnologies Inc. (NASDAQ:LBIO) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $9.58 and last traded at $9.54, with a volume of 206,483 shares traded. The stock had previously closed at $9.05.
A number of analysts have issued reports on the company. Zacks Investment Research downgraded Lion Biotechnologies from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. Roth Capital reissued a “buy” rating and issued a $15.00 target price on shares of Lion Biotechnologies in a research report on Saturday, July 9th. FBR & Co reissued a “buy” rating on shares of Lion Biotechnologies in a research report on Monday, June 6th. SunTrust Banks Inc. downgraded Lion Biotechnologies from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $37.00 to $30.50 in a research report on Monday, June 6th. Finally, Chardan Capital reissued a “buy” rating on shares of Lion Biotechnologies in a research report on Saturday, June 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $19.17.
The company’s market capitalization is $542.87 million. The company has a 50-day moving average price of $8.44 and a 200-day moving average price of $6.40.
Lion Biotechnologies (NASDAQ:LBIO) last issued its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.04. On average, equities research analysts anticipate that Lion Biotechnologies Inc. will post ($0.76) EPS for the current fiscal year.
Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.